Alcidion Expands Partnership with NextGate to UK Market

Alcidion LtdSmart health tech provider Alcidion Group Limited (ASX:ALC) has announced an expansion of its reseller agreement with NextGate to include the UK and Ireland.

In 2018, MKM Health (which was acquired by Alcidion in 2018) signed an agreement to resell NextGate's market leading Enterprise Master Patient Index (EMPI) and Provider Registry solutions in Australia and New Zealand. Following a successful two-year relationship, this agreement has now been extended to also include the UK and Ireland.

NextGate is the global leader in healthcare enterprise identification, helping healthcare organisations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data.

Alcidion's reseller agreement with NextGate has resulted in two significant state-wide contracts in Australia. The Queensland Health Referral Service Directory based on the Provider Index was delivered by Alcidion working closely with NextGate. For the Victorian Department of Health and Human Services Unique Patient Identification program, Alcidion supported NextGate in delivery of its EMPI capability.

The expansion of the agreement to the UK and Ireland will further strengthen Alcidion's ability to support NHS trusts, health boards and region wide integrated care systems. The news follows the Alcidion's formal launch this summer of its Miya Precision product as the first smart clinical asset for the NHS.

Lynette Ousby, UK General Manager of Alcidion, said: "With the current focus in the NHS on consolidating clinical systems across regions, the ability to include the offering of NextGate solutions to complement our Miya Precision capability, establishes a true enterprise approach to healthcare delivery."

Alcidion's Miya Precision presents the NHS with an opportunity to move beyond static electronic records to technology that engages healthcare professionals. Early adopters are using the platform to orchestrate information across disparate systems using modern technology from Alcidion based on the FHIR standard and to establish smart clinical engagement supported by tailored clinical decision support.

With the ability to allow NHS organisations to use data to automate routine tasks, care plans and pathways, Miya Precision is being seen as a way to realise more value from electronic patient record investments and to provide a technology orchestration layer in trusts and for entire regions.

The addition of the NextGate Patient and Provider Registries, which are built on the MatchMetrix® master identity platform, will extend that capability to effectively manage identity for both patients and healthcare providers.

"We are delighted to expand our partnership with Alcidion to facilitate a modernised NHS infrastructure where patients are accurately identified and consistently matched to their health and social care data," said Andy Aroditis, CEO of NextGate. "Together, Alcidion and NextGate are delivering innovative interoperable solutions that maximise the quality, efficiency and coordination of care."

Alcidion Managing Director, Kate Quirke commented: "I am delighted that we can now expand our success implementing the NextGate solution in Australia to the UK. The combination of our service delivery and domain expertise with the powerful capabilities of MatchMetrix creates a compelling opportunity for the health sector to establish first class identity management."

About NextGate

With over 200 customers in six countries, NextGate is the global leader in healthcare enterprise identification. Committed to helping organizations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data, our full suite of identity matching solutions connects the entire healthcare ecosystem to drive critical improvements in quality, efficiency and safety. NextGate’s market leading EMPI currently manages 300 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges.

About Alcidion

Alcidion (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...